Trial Profile
Randomized, Open Label, Multicenter Study Assessing The Clinical Benefit Of Isatuximab Combined With Carfilzomib (Kyprolis) And Dexamethasone Versus Carfilzomib With Dexamethasone In Patients With Relapse And/Or Refractory Multiple Myeloma Previously Treated With 1 to 3 Prior Lines
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 15 Mar 2024
Price :
$35
*
At a glance
- Drugs Isatuximab (Primary) ; Carfilzomib; Dexamethasone; Dexamethasone
- Indications Multiple myeloma
- Focus Registrational; Therapeutic Use
- Acronyms IKEMA
- Sponsors Sanofi; Sanofi-Aventis Recherche & Developpement
- 01 Mar 2024 Results of subgroup analysis assessing safety and efficacy of Isatuximab in combination with carfilzomib and dexamethasone in 1q21+ patients with relapsed/refractory multiple myeloma published in the Hematological Oncology
- 07 Nov 2023 Planned End Date changed from 26 Apr 2024 to 19 Nov 2024.
- 01 Oct 2023 Results of updated analysis of the efficacy and safety of Isa-Kd in East Asian patients, including data through 14 January 2022, published in the Clinical Lymphoma, Myeloma & Leukemia